Protecting Insulin-Producing Cells for Diabetes Treatment
Hydrogels for human beta cell survival, function and evasion of immune rejection
This project is developing special materials to help transplanted insulin-producing cells survive and work better in people with Type 1 diabetes, without needing strong immune-suppressing medicines.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11088282 on NIH RePORTER |
What this research studies
Type 1 diabetes happens when the body's immune system destroys the cells that make insulin. While transplanting new insulin-producing cells can help, they often don't last long and require strong medications to prevent rejection. This project is creating special protective materials, called hydrogels, to deliver these new cells. These hydrogels are designed to help the cells get the blood supply they need, survive better, and avoid being attacked by the immune system. The hope is to make cell replacement therapy safer and more effective for people with Type 1 diabetes.
Who could benefit from this research
Good fit: This research is ultimately for individuals with Type 1 diabetes who might benefit from cell replacement therapies.
Not a fit: Patients not seeking or eligible for cell replacement therapies would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this could offer a new way to treat Type 1 diabetes by restoring the body's natural insulin production, potentially reducing the need for daily insulin shots and strong anti-rejection medications.
How similar studies have performed: While cell transplantation for Type 1 diabetes has shown promise in clinical trials, current methods for protecting these cells have faced challenges, making this project's advanced biomaterial approach novel.
Where this research is happening
Atlanta, United States
- Georgia Institute of Technology — Atlanta, United States (Active)
Researchers
- Principal investigator: Garcia, Andres J — Georgia Institute of Technology
- Study coordinator: Garcia, Andres J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.